IPHA News and Press, Innate Pharma S.A. From 11/13/25

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dos...

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of systemic therapy. The Company submitted the confirmatory Phase 3 TELLOMAK 3 protoc...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progr...

2025-10-29 06:37:39 ET from H.C. Wainwright issued a price target of $5.00 for IPHA on 2025-10-29 10:09:36. The adjusted price target was set to $5.00. At the time of the announcement, IPHA was trading at $2.09. The overall price target consensus is at $2.00 with high pr...

2025-10-28 18:21:51 ET Innate Pharma S.A. (IPHA) Analyst/Investor Day October 28, 2025 8:00 AM EDT Company Participants Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Stéphanie Cornen Stephanie Cornen -...

The event will provide clinical perspectives and market outlook for lacutamab, Innate’s lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase 3 initiation Leading KOL Pierluigi Porcu, M.D., a world expert in T-cell lymphomas, will ...

2025-09-17 14:45:13 ET More on Innate Pharma Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript Innate Pharma S.A. 2025 Q2 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Innate Pharma Historical earnings data for Innate ...

2025-09-17 11:43:48 ET Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call September 17, 2025 8:00 AM EDT Company Participants Stéphanie Cornen Jonathan Dickinson - CEO & Director Yannis Morel - Executive VP & COO Sonia Quaratino - Executive VP &...

null (VMCAF) is expected to report for quarter end 2025-06-30 Pinstripes Holdings Inc - Class A (PNSTQ) is expected to report for Q1 2026 Mountain Valley MD Holdings Inc (MVMDF) is expected to report for quarter end 2025-06-30 Movano Inc. (MOVE) is expected to report for quarter end 2...

Innate Pharma S.A. (IPHA) is expected to report for Q2 2025